Companies: 48,687 Total Market Cap: 127291036954077.85

Vaxcyte

NASDAQ: PCVX
Healthcare Biotechnology
Rank #3325
Market Cap 4.57 B
Volume 1.94 M
Price 35.39
Change (%) 0.43%
Country or region United States United States

Vaxcyte's latest marketcap:

4.57 B

As of May 4, 2025, Vaxcyte's market capitalization has reached $4.57 B. According to our data, Vaxcyte is the 3325th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 4.57 B
Revenue (ttm) 0
Net Income (ttm) -463,927,000
Shares Out 129.00 M
EPS (ttm) -3.80
Forward PE 0.00
Ex-Dividend Date n/a
Earnings Date May 12, 2025
Market Cap Chart
Data Updated: May 4, 2025

Vaxcyte's yearly market capitalization.

Vaxcyte has seen its market value grow from $1.35 B to $4.57 B since 2020, representing a total increase of 237.24% and an annual compound growth rate (CAGR) of 32.38%.
Date Market Cap Change (%)
May 2, 2025 $4.57 B -55.25%
December 31, 2024 $10.20 B 70.74%
December 29, 2023 $5.98 B 57.79%
December 30, 2022 $3.79 B 201.58%
December 31, 2021 $1.26 B -7.24%
December 31, 2020 $1.35 B

Company Profile

About Vaxcyte, Inc.

Vaxcyte, Inc. is a clinical-stage biotechnology company focused on developing innovative vaccines to prevent or treat bacterial infectious diseases. The company specializes in conjugate and novel protein vaccines designed to address critical health challenges.

Key Vaccine Candidates

  • VAX-24: A 24-valent, carrier-sparing investigational pneumococcal conjugate vaccine (PCV) targeting invasive pneumococcal disease (IPD).
  • VAX-31: A 31-valent, carrier-sparing investigational PCV for IPD prevention in adults and children.
  • VAX-A1: A novel conjugate vaccine candidate for preventing Group A Streptococcus infections.
  • VAX-PG: A protein vaccine candidate aimed at combating periodontitis-causing pathogens.
  • VAX-GI: A vaccine candidate targeting dysentery and shigellosis.

Company Background

Originally founded as SutroVax, Inc. in 2013, the company rebranded as Vaxcyte, Inc. in May 2020. Headquartered in San Carlos, California, Vaxcyte is dedicated to advancing next-generation vaccine solutions.

Frequently Asked Questions

As of May 4, 2025, Vaxcyte (including the parent company, if applicable) has an estimated market capitalization of $4.57 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Vaxcyte global market capitalization ranking is approximately 3325 as of May 4, 2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region United States
Founded 2013
IPO Date June 12, 2020
Employees 414
CEO Grant Pickering
Sector Healthcare
Industry Biotechnology
Address 825 Industrial Road, Suite 300
San Carlos, California 94070
United States
People Also Watch
VRTX
501.15 0.43%
ASX-CSL
165.14 0.43%
REGN
605.61 0.43%
KRX-207940
770.35 0.43%